OBJECTIVE: To evaluate concurrent administration of mecamylamine (nicotine antagonist) with nicotine skin patch treatment for smoking cessation. METHODS: This was a randomized, double-blind, placebo-controlled trial. Forty-eight healthy smokers who smoked at least one pack per day were studied at an outpatient smoking cessation research clinic. The subjects ranged in age from 20 to 40 years. Intervention with the nicotine skin patch (6 to 8 weeks) plus oral mecamylamine (2.5 to 5 mg twice a day for 5 weeks) was compared to nicotine patch plus placebo. Mecamylamine treatment began 2 weeks before smoking cessation. The primary outcome was continuous abstinence through 7 weeks after cessation (1 week after treatment), confirmed by expired air carbon monoxide measurements. Secondary measures included point abstinence at 7 weeks, continuous abstinence at 6- and 12-month follow-up, and self-reported withdrawal symptoms. RESULTS: The continuous abstinence rate at 7 weeks was three times higher in the mecamylamine condition: 50% versus 16.7%, p = 0.015. Point abstinence at 7 weeks was 58% for mecamylamine versus 29% for placebo, p = 0.044. At follow-up, continuous abstinence remained higher for mecamylamine: 37.5% versus 12.5% at 6 months (p = 0.046) and 37.5% versus 4.2% at 12 months (p = 0.004). Mecamylamine also significantly reduced craving for cigarettes, negative affect, and appetite. CONCLUSIONS: Agonist-antagonist therapy, consisting of the nicotine patch with oral mecamylamine, may substantially improve current smoking cessation treatment.
RCT Entities:
OBJECTIVE: To evaluate concurrent administration of mecamylamine (nicotine antagonist) with nicotine skin patch treatment for smoking cessation. METHODS: This was a randomized, double-blind, placebo-controlled trial. Forty-eight healthy smokers who smoked at least one pack per day were studied at an outpatient smoking cessation research clinic. The subjects ranged in age from 20 to 40 years. Intervention with the nicotine skin patch (6 to 8 weeks) plus oral mecamylamine (2.5 to 5 mg twice a day for 5 weeks) was compared to nicotine patch plus placebo. Mecamylamine treatment began 2 weeks before smoking cessation. The primary outcome was continuous abstinence through 7 weeks after cessation (1 week after treatment), confirmed by expired air carbon monoxide measurements. Secondary measures included point abstinence at 7 weeks, continuous abstinence at 6- and 12-month follow-up, and self-reported withdrawal symptoms. RESULTS: The continuous abstinence rate at 7 weeks was three times higher in the mecamylamine condition: 50% versus 16.7%, p = 0.015. Point abstinence at 7 weeks was 58% for mecamylamine versus 29% for placebo, p = 0.044. At follow-up, continuous abstinence remained higher for mecamylamine: 37.5% versus 12.5% at 6 months (p = 0.046) and 37.5% versus 4.2% at 12 months (p = 0.004). Mecamylamine also significantly reduced craving for cigarettes, negative affect, and appetite. CONCLUSIONS: Agonist-antagonist therapy, consisting of the nicotine patch with oral mecamylamine, may substantially improve current smoking cessation treatment.
Authors: Brandon J Henderson; Ryan E Pavlovicz; Jerad D Allen; Tatiana F González-Cestari; Crina M Orac; Andrew B Bonnell; Michael X Zhu; R Thomas Boyd; Chenglong Li; Stephen C Bergmeier; Dennis B McKay Journal: J Pharmacol Exp Ther Date: 2010-06-15 Impact factor: 4.030
Authors: Thomas J Gould; George S Portugal; Jessica M André; Matthew P Tadman; Michael J Marks; Justin W Kenney; Emre Yildirim; Michael Adoff Journal: Neuropharmacology Date: 2012-01-21 Impact factor: 5.250
Authors: Brandon J Henderson; Crina M Orac; Iwona Maciagiewicz; Stephen C Bergmeier; Dennis B McKay Journal: Bioorg Med Chem Lett Date: 2011-11-20 Impact factor: 2.823
Authors: Brandon J Henderson; Daniel J Carper; Tatiana F González-Cestari; Bitna Yi; Kiran Mahasenan; Ryan E Pavlovicz; Martin L Dalefield; Robert S Coleman; Chenglong Li; Dennis B McKay Journal: J Med Chem Date: 2011-11-18 Impact factor: 7.446
Authors: Amanda M Struthers; Jamie L Wilkinson; Linda P Dwoskin; Peter A Crooks; Rick A Bevins Journal: Pharmacol Biochem Behav Date: 2009-09-22 Impact factor: 3.533
Authors: Zhenfa Zhang; Guangrong Zheng; Marharyta Pivavarchyk; A Gabriela Deaciuc; Linda P Dwoskin; Peter A Crooks Journal: Bioorg Med Chem Lett Date: 2008-09-26 Impact factor: 2.823